Sibel Blau, MD, President/CEO of the Quality Cancer Care Alliance Network (QCCA) and Medical Director of Northwest Medical Specialties, presented the different operational models used in the ELAINE2 study at ASCO 2022. In this oral presentation, Dr. Blau compared the traditional approach to trial enrollment with a Just-in-Time (JIT) model reviewing the operational metrics of both models to explain the unique and novel approach of JITs. The development and integration of JIT trials into oncology is a major development that will improve the accrual of patients into clinical trials, benefiting all cancer patients, especially in their own communities where they are treated in community cancer practices. QCCA, soon to be a part of Exigent Research, took a part in this very important approach to helping patients. #QCCA #FiercelyIndependent #DrSibelBlau
https://www.linkedin.com/feed/update/urn:li:activity:6940649859301482496